Short-term outcomes of chemoradiotherapy and local excision versus total mesorectal excision in T2-T3ab,N0,M0 rectal cancer: a multicentre randomised, controlled, phase III trial (the TAU-TEM study)

医学 全直肠系膜切除术 外科 结直肠癌 放化疗 置信区间 随机对照试验 不利影响 癌症 内科学 化疗
作者
Xavier Serra‐Aracil,Carles Pericay,Jesus Badía-Closa,Thomas Golda,Sebastiano Biondo,Pau Joan Hernández,Eduardo M. Targarona,Nerea Borda-Arrizabalaga,Angel Antonio Pozuelo Reina,S. Delgado,Francesc Vallribera,Antonia Caro,Javier Gállego,Marta Pascual,Carlos Álvarez-Laso,Héctor Guadalajara,Laura Mora
出处
期刊:Annals of Oncology [Elsevier BV]
卷期号:34 (1): 78-90 被引量:80
标识
DOI:10.1016/j.annonc.2022.09.160
摘要

The standard treatment of T2-T3ab,N0,M0 rectal cancers is total mesorectal excision (TME) due to the high recurrence rates recorded with local excision. Initial reports of the combination of pre-operative chemoradiotherapy (CRT) and transanal endoscopic microsurgery (TEM) have shown reductions in local recurrence. The TAU-TEM study aims to demonstrate the non-inferiority of local recurrence and the improvement in morbidity achieved with CRT-TEM compared with TME. Here we describe morbidity rates and pathological outcomes.This was a prospective, multicentre, randomised controlled non-inferiority trial including patients with rectal adenocarcinoma staged as T2-T3ab,N0,M0. Patients were randomised to the CRT-TEM or the TME group. Patients included, tolerance of CRT and its adverse effects, surgical complications (Clavien-Dindo and Comprehensive Complication Index classifications) and pathological results (complete response in the CRT-TEM group) were recorded in both groups. Patients attended follow-up controls for local and systemic relapse.NCT01308190.From July 2010 to October 2021, 173 patients from 17 Spanish hospitals were included (CRT-TEM: 86, TME: 87). Eleven were excluded after randomisation (CRT-TEM: 5, TME: 6). Modified intention-to-treat analysis thus included 81 patients in each group. There was no mortality after CRT. In the CRT-TEM group, one patient abandoned CRT, 1/81 (1.2%). The CRT-related morbidity rate was 29.6% (24/81). Post-operative morbidity was 17/82 (20.7%) in the CRT-TEM group and 41/81 (50.6%) in the TME group (P < 0.001, 95% confidence interval 42.9% to 16.7%). One patient died in each group (1.2%). Of the 81 patients in the CRT-TEM group who received the allocated treatment, 67 (82.7%) underwent organ preservation. Pathological complete response in the CRT-TEM group was 44.3% (35/79). In the TME group, pN1 were found in 17/81 (21%).CRT-TEM treatment obtains high pathological complete response rates (44.3%) and a high CRT compliance rate (98.8%). Post-operative complications and hospitalisation rates were significantly lower than those in the TME group. We await the results of the follow-up regarding cancer outcomes and quality of life.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
我忘了李发布了新的文献求助10
1秒前
2秒前
兮颜发布了新的文献求助30
3秒前
3秒前
优秀的小丸子完成签到,获得积分10
4秒前
人间慈悲的应助被胡平采纳,获得10
4秒前
4秒前
4秒前
sun完成签到,获得积分10
5秒前
6秒前
8秒前
8秒前
彭于晏的应助被liuqc采纳,获得10
8秒前
田様的应助被Esther采纳,获得10
8秒前
Jiang完成签到,获得积分10
8秒前
王长长完成签到,获得积分10
9秒前
泡泡123123完成签到,获得积分10
9秒前
Ava的应助被我忘了李采纳,获得10
9秒前
9秒前
蝈蝈崽发布了新的文献求助10
10秒前
阔达的夜山完成签到,获得积分10
10秒前
Hello的应助被hky采纳,获得10
10秒前
KimGyuvin发布了新的文献求助10
11秒前
Menand发布了新的文献求助10
11秒前
平常寒烟发布了新的文献求助10
14秒前
沉默的从安完成签到,获得积分10
14秒前
15秒前
蝈蝈崽完成签到,获得积分10
15秒前
16秒前
无花果的应助被霍则风采纳,获得20
17秒前
17秒前
17秒前
秋风的应助被霍则风采纳,获得10
17秒前
秋风的应助被霍则风采纳,获得20
17秒前
我是老大的应助被坚强孤容采纳,获得10
17秒前
秋风的应助被霍则风采纳,获得20
17秒前
xing_xing的应助被霍则风采纳,获得20
17秒前
秋风的应助被霍则风采纳,获得20
17秒前
xing_xing的应助被霍则风采纳,获得100
17秒前
秋风的应助被霍则风采纳,获得20
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8186784
求助须知:如何正确求助?哪些是违规求助? 9575092
关于积分的说明 21839541
捐赠科研通 7784418
什么是DOI,文献DOI怎么找? 3434819
关于科研通互助平台的介绍 2559221
邀请新用户注册赠送积分活动 2481682